Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.
Vision Pixium organize an open dayfor investors October 13e 2022 of 5 p.m.
Registration Required – Limited Availability
Paris, France, September 21, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live a more independent life, announces today today that it will host an open house for investors on Thursday, October 13, 2022.
The event, which will take place from 5:00 p.m. to 7:00 p.m. CET, will be conducted in French and will include an introduction by Lloyd Diamond, CEO, and Brian Burg, Director of R&D, on Pixium Vision and its bionic vision Prima System, upcoming clinical stages and development, and an overview of Dry Age-Related Macular Degeneration Diseases (AMD) and the market landscape. There will be a guided tour of the Pixium Vision laboratories including a technological demonstration. The event will end with an aperitif to discuss directly with the Pixium Vision team and use virtual reality to better understand the Prima system.
The Prima system, which has the potential to significantly improve the lives of patients with dry AMD, is being studied in the pivotal PRIMAvera study which aims to confirm its safety and benefits and is the final clinical step before requesting marketing authorization in Europe. The study was launched in the fourth quarter of 2020 in France and clinical sites have also been established in Germany, the United Kingdom, the Netherlands and Italy. Patient recruitment was completed recently, providing the confidence to achieve the goal of implanting all PRIMAvera patients through the end of 2022, leading to a reading of the PRIMAvera study towards the end of 2023.
Registration:Participation in the event is restricted to current investors! Please register here to register for the event, which will be held at Pixium Vision’s premises in Paris. . Please note that the registration link will be deleted as soon as the maximum capacity is reached.
About Vision Pixium
Vision Pixium creates a world of bionic vision for those who have lost their sight, allowing them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with surgery and a period of rehabilitation. The Prima System subretinal wireless miniature photovoltaic implant is in clinical trial for patients who have lost sight due to outer retinal degeneration, initially for dry age-related atrophic macular degeneration (dry AMD). Pixium Vision works closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, the Institute of Ocular Microsurgery (IMO) in Barcelona, the University Hospital of Bonn and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualified as an “Innovative Company” by Bpifrance.
Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of the risks and uncertainties that could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors section (” Risk factors”) of the Company’s 2021 report. Half-year financial report and other documents filed by the Company with the AMF, available on the AMF’s website (www.amf-france.org) or on the Company’s website.
For more information: http://www.pixium-vision.com/en
follow us on @PixiumVision; www.facebook.com/pixiumvision
Source: Pixium Vision